HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Laurent O Mosnier Selected Research

Factor Va

1/2022An engineered activated factor V for the prevention and treatment of acute traumatic coagulopathy and bleeding in mice.
11/2020An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms.
1/2016Safety, Stability and Pharmacokinetic Properties of (super)Factor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding.
1/2014An engineered factor Va prevents bleeding induced by anticoagulant wt activated protein C.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Laurent O Mosnier Research Topics

Disease

22Hemorrhage
01/2022 - 09/2004
8Sepsis (Septicemia)
01/2018 - 09/2004
7Ischemic Stroke
01/2019 - 04/2012
6Inflammation (Inflammations)
11/2022 - 01/2009
6Hemophilia A (Haemophilia)
12/2020 - 01/2002
4Thrombosis (Thrombus)
01/2020 - 09/2006
4Malaria
01/2019 - 01/2014
4Stroke (Strokes)
01/2018 - 09/2006
3Endotoxemia
04/2013 - 10/2007
2Central Nervous System Cavernous Hemangioma
01/2019 - 01/2019
2Cerebral Malaria
01/2019 - 11/2015
2Joint Diseases (Joint Disease)
01/2016 - 11/2015
2Purpura Fulminans
04/2012 - 04/2007
2Venous Thrombosis (Deep-Vein Thrombosis)
04/2012 - 04/2007
2Activated Protein C Resistance (APC Resistance)
03/2012 - 04/2007
1Atherosclerosis
11/2022
1Myocardial Infarction
01/2020
1Reperfusion Injury
01/2020
1Hemarthrosis
11/2019
1Vascular Remodeling
10/2019
1Graft vs Host Disease (Graft-Versus-Host Disease)
01/2019
1Alzheimer Disease (Alzheimer's Disease)
01/2019
1Ischemia
11/2016
1Thrombotic Stroke
11/2016
1Epidural Abscess
03/2016
1Herpes Zoster
11/2014
1Lacerations
01/2014
1Edema (Dropsy)
08/2013
1Infarction (Infarctions)
08/2013
1Albuminuria
04/2013
1Weight Loss (Weight Reduction)
04/2013
1Vascular Diseases (Vascular Disease)
01/2013
1Neurodegenerative Diseases (Neurodegenerative Disease)
01/2013
1Peritonitis
10/2007

Drug/Important Bio-Agent (IBA)

21Protein CIBA
12/2020 - 09/2004
14AnticoagulantsIBA
12/2020 - 09/2004
9Endothelial Protein C ReceptorIBA
01/2019 - 10/2007
6Proteins (Proteins, Gene)FDA Link
05/2016 - 10/2007
5Factor VIII (Coagulation Factor VIII)IBA
11/2019 - 01/2018
4Factor VaIBA
01/2022 - 01/2014
4Carboxypeptidase B2 (Thrombin Activatable Fibrinolysis Inhibitor)IBA
10/2019 - 01/2002
3Tissue Plasminogen Activator (Alteplase)FDA Link
12/2018 - 11/2016
3PAR-1 ReceptorIBA
12/2018 - 03/2009
3ThrombinFDA Link
03/2016 - 03/2009
2DisulfidesIBA
01/2022 - 11/2020
2ThrombomodulinIBA
01/2019 - 01/2011
2Biomarkers (Surrogate Marker)IBA
01/2019 - 01/2016
2Blood Coagulation Factors (Coagulation Factor)IBA
01/2016 - 11/2015
2Factor V (Coagulation Factor V)IBA
01/2016 - 04/2012
2Pharmaceutical PreparationsIBA
11/2014 - 01/2002
2Biological ProductsIBA
11/2014 - 01/2013
2Therapeutic UsesIBA
01/2014 - 09/2004
2BradykininIBA
01/2011 - 11/2007
1Kallikreins (Kallikrein)IBA
11/2022
1Apolipoproteins E (ApoE)IBA
11/2022
1Peptide Hydrolases (Proteases)FDA Link
11/2022
1Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA
11/2022
1Serine Proteases (Serine Protease)IBA
11/2022
1Monoclonal AntibodiesIBA
12/2020
1FIIaIBA
11/2020
1Factor Xa InhibitorsIBA
11/2020
1apixabanIBA
11/2020
1DabigatranFDA Link
11/2020
1RivaroxabanIBA
11/2020
1Troponin IIBA
01/2020
1FibrinIBA
01/2020
1PlasminogenIBA
10/2019
1Blocking AntibodiesIBA
01/2019
1InflammasomesIBA
01/2019
1G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
12/2018
1Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
10/2018
1Polymethyl Methacrylate (Sol)IBA
11/2016
1activated protein C receptorIBA
11/2016
1artemisinin (artemisinine)IBA
05/2016
1Factor VIIa (Activated Factor VII)IBA
03/2016
1A-factor (Streptomyces)IBA
03/2016
1Plasmodium falciparum erythrocyte membrane protein 1IBA
11/2015
1Peptides (Polypeptides)IBA
11/2014
1LigandsIBA
11/2014
1Hemoglobins (Hemoglobin)IBA
08/2013
1Evans Blue (Blue, Evans)FDA Link
04/2013
1LipopolysaccharidesIBA
04/2013
1Neuroprotective AgentsIBA
04/2012
1Protein SIBA
04/2012
1HDL LipoproteinsIBA
04/2012
1LipidsIBA
04/2012
1Heparin (Liquaemin)FDA LinkGeneric
01/2011
1Antifibrinolytic Agents (Antifibrinolytics)IBA
01/2011
1EndotoxinsIBA
06/2009
1CoagulantsIBA
03/2009
1CarboxypeptidasesIBA
11/2007
1factor V LeidenIBA
04/2007
1EnzymesIBA
09/2004
1EndostatinsIBA
06/2003
1Collagen Type XVIII (Type XVIII Collagen)IBA
06/2003

Therapy/Procedure

12Therapeutics
12/2020 - 09/2004
1Craniotomy
03/2016
1Surgical Instruments (Clip)
01/2014
1Aftercare (After-Treatment)
08/2013
1Stents
10/2007